The arrival of biosimilars has led to considerable debate on how they can be used in clinical practice. A particular concern is related to the question of whether a biosimilar can be safely interchanged with the originator product or other biosimilars. Here we will discuss challenges to the regulatory approach for establishing interchangeability, in
No takes yet. Share an insight, caveat, or question.
Ebbers et al. (2014) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: